JP Morgan Initiates Coverage On Relay Therapeutics with Overweight Rating, Announces Price Target of $28
Benzinga Newsdesk 4 months ago
NewsInitiationAnalyst RatingsPrice Target
JP Morgan analyst Priyanka Grover initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Overweight rating and announces Price Target of $28.
JP Morgan analyst Priyanka Grover initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Overweight rating and announces Price Target of $28.